Kola Hisamuddin

Case Western Reserve University, Cleveland, Ohio, United States

Are you Kola Hisamuddin?

Claim your profile

Publications (6)35.68 Total impact

  • Kola Hisamuddin · Chandra Veluru · Kevin D Mullen ·

    Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 11/2008; 7(6):A24. DOI:10.1016/j.cgh.2008.10.020 · 7.90 Impact Factor
  • Kola Hisamuddin · Christopher P Brandt ·

    Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 04/2008; 6(3):A28-A28.e1. DOI:10.1016/j.cgh.2007.12.013 · 7.90 Impact Factor
  • Kola Hisamuddin · Satish Iduru · Kevin D Mullen ·

    Nature Clinical Practice Gastroenterology &#38 Hepatology 04/2008; 5(3):132-3. DOI:10.1038/ncpgasthep1027 · 5.33 Impact Factor
  • Kola Hisamuddin · Kevin D. Mullen ·

    Evidence-Based Gastroenterology 11/2007; 8(4):77-78. DOI:10.1097/EBG.0b013e31815acfcd
  • Satish Iduru · Kola Hisamuddin · Kevin D Mullen ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Minimal hepatic encephalopathy (MHE) is relatively common and has a significant effect on the quality of life in patients with cirrhosis. However, diagnosing this entity clinically can be quite challenging. Inhibitory control testing (ICT) as a screening tool for diagnosis of MHE has been used clinically for sometime. The study published in this issue to validate ICT as a screening modality for MHE suggests it is a relatively simply, reliable test and can be easily administered by ancillary staff in the clinic. The study demonstrates that ICT has the potential to become a popular diagnostic tool for the diagnosis of MHE. A multicenter study to further validate the system for wider use will further strengthen the argument for its use in every patient with cirrhosis.
    The American Journal of Gastroenterology 08/2007; 102(7):1537-8. DOI:10.1111/j.1572-0241.2007.01188.x · 10.76 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We examined the temporal relationship between portacaval anastomosis (PCA), weight gain, changes in skeletal muscle mass and molecular markers of protein synthesis, protein breakdown, and satellite cell proliferation and differentiation. Male Sprague-Dawley rats with end to side PCA (n=24) were compared with sham-operated pair-fed rats (n=24). Whole body weight, lean body mass, and forelimb grip strength were determined at weekly intervals. The skeletal muscle expression of the ubiquitin proteasome system, myostatin, its receptor (the activin 2B receptor) and its signal, cyclin-dependent kinase inhibitor (CDKI) p21, insulin-like growth factor (IGF)-I and its receptor (IGF-I receptor-alpha), and markers of satellite cell proliferation and differentiation were quantified. PCA rats did not gain body weight and had lower lean body mass, forelimb grip strength, and gastrocnemius muscle weight. The skeletal muscle expression of the mRNA of ubiquitin proteasome components was higher in PCA rats in the first 2 wk followed by a lower expression in the subsequent 2 wk (P<0.01). The mRNA and protein of myostatin, activin 2B receptor, and CDKI p21 were higher, whereas IGF-I and its receptor as well as markers of satellite cell function (proliferating nuclear cell antigen, myoD, myf5, and myogenin) were lower at weeks 3 and 4 following PCA (P < 0.05). We conclude that PCA resulted in uninhibited proteolysis in the initial 2 wk. This was followed by an adaptive response in the later 2 wk consisting of an increased expression of myostatin that may have contributed to reduced muscle protein synthesis, impaired satellite cell function, and lower skeletal muscle mass.
    AJP Gastrointestinal and Liver Physiology 04/2007; 292(4):G1105-13. DOI:10.1152/ajpgi.00529.2006 · 3.80 Impact Factor